Latest Breaking News On - Christopher delorefice - Page 1 : comparemela.com

Becton, Dickinson and Company (NYSE:BDX) Q1 2024 Earnings Call Transcript

Becton, Dickinson and Company (NYSE:BDX) Q1 2024 Earnings Call Transcript February 1, 2024 Becton, Dickinson and Company beats earnings expectations. Reported EPS is $2.68, expectations were $2.39. Becton, Dickinson and Company isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and welcome […]

How the incoming governor can restore public trust in the Health Department

Plus: H+H to extend affiliation deal with SUNY Downstate for up to $24.7M Jewish Board files layoff notice for Bronx, Westchester locations Brooklyn menopause telehealth startup raises $3.8M seed round

J&J's DelOrefice to join BD as CFO

BD (Becton, Dickinson and Co.) said Christopher DelOrefice was named executive vice president and chief financial officer, effective Sept. 6.

Janssen Submits New Drug Application to U.S. FDA for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients

New Phase 3 Study Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed

GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual CongressBEERSE, Belgium (BUSINESS WIRE) The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVI.